

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
Sheet	1	of	1
<b>Application Number</b> 10/077,698 <b>Filing Date</b> February 13, 2002 <b>First Named Inventor</b> Glucksmann, Maria A., et al. <b>Group Art Unit</b> 1646 <b>Examiner Name</b> Brannock, Michael T. <b>Attorney Docket Number</b> MPI98-047CP2DVIM			

<b>OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS</b>		
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	A12	Mansson, E., et al. "Kappa-Type Opioid Receptor (KOR-1)," created February 1, 1995 (sequence) GenPept [online]. Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on May 4, 2005]. Retrieved from the Internet: URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> SwissProt Accession No. P41145.

Examiner Signature	<i>Michael</i>	Date Considered	7/18/05
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.